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a sociological commentary
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This study provides a sociological commentary on the current debates within health
technology assessment (HTA), specifically in response to the approaches taken in France,
The Netherlands, Sweden, and the United Kingdom. It argues that HTA is part of a wider
reflexive innovation system that seeks to order current and prospective technologies. The
study discusses the socio-political process of HTA priority setting, the rhetorical role of
HTA, the localised and contingent use of HTA, and the policy gap between guidelines and
practice. It argues for the development of new types of methodologies for assessment and
for a stronger social embedding of HTA practice.
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Precisely because health technologies are undergoing
continual innovation, their “scientific basis” and utility for
health services is increasingly scrutinized. The interactions
between commercial technology innovation and service de-
livery/organization are crucial to health policy development,
as are the social, economic, and organizational aspects of the
“redesign” of healthcare. “Early warning” about technologies
seen to have economic, social, and clinical significance has
been identified as a major priority, raising both technical (19)
and social questions (3).
A sociological exploration of the ideas and practices of
health technology assessment (HTA) is distinctive in attempt-
ing to unpack the social meaning of HTA, its assumptions
and ways of ordering the world, and the social relationships
between those involved in constructing its reports and rec-
ommendations. As Zygmunt Bauman (18) recently argued,
sociology is concerned with “decoding the meaning of human
actions in reference to social conditions.” As have many other
theorists (10;14) exploring modernity and its risk-generative
culture, Bauman also argues that our social condition is one
of “ambivalence.” It is, in part, our response to this wider
social condition that has spurred the arrival of multiple tech-
niques for surveillance, audit, and control, including the raft
of models for measuring and evaluating the costs, benefits,
and the effectiveness of the products of modernity—such as
health technologies.
In this regard, we might construe HTA as one of sev-
eral “political machines” (1) that regulate both technology
and its socio-political positioning at the same time. Barry
(1) describes the ways in which government and its agencies
construct what he calls “technological zones” that reflect very
specific regulatory and technological regimes. Standardized
measures of technologies are a key dimension not only of a
technical but also a political ordering and control; however,
new technical developments simultaneously work to under-
mine these same standards. As he says:
“standardisation is both expected to reduce blockages and restric-
tions in the circulation of technology . . . [while at the same time] the
development of technology continually destabilises existing stan-
dards . . . [and may create] political conflict.” (p. 63).
Barry’s account of the standardizing process reflects
many features of HTA used to regulate the introduction of
new health technologies: the attempt to order and facilitate
the dissemination of technology that meets a specific set of
standards, coupled with the ever-present need to manage this
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dissemination in a politically legitimate and economically
efficient way.
In historical terms, we can also see how HTA comes at
a time when the primary social discourse that runs through
all institutional structures is not only about surveillance (16)
but is also one of responsibility and reflexivity. Responsibility
here refers to the sense of having to make an account (both sci-
entific and economic) to others not only of the application but
also the implication a new technology has (17); and reflexivity
in the sense of acknowledging the inherent provisionality to
such accounts and the need to make explicit or “transparent”
(4) the basis on which claims are made. Strydom (21) has
argued that there have been three great discourses of moder-
nity that have shaped the historical ordering of science and
technology from the enlightenment period through to today:
these are a discourse of “rights” (in the 16th-18th centuries),
of “justice” (in the 19th to mid-20th), and of “responsibility”
(today). In each case the problem for society—and the “so-
cial conditions” that need to be addressed—is different. The
most relevant for the discussion here, the responsibility dis-
course, appears in response to the “ambivalence” and uncer-
tainties created by our engagement with and deconstruction of
“nature”, principally through the new biosciences and genet-
ics. The innovation we find today breaks down conventional
boundaries between species, humans and machines (the cy-
borg), humans and animals (the xenotransplant), and humans
and humans (e.g. in vitro fertilization, embryonic stem cells,
etc.).
Contemporary health technologies are increasingly
caught up in these new forms of innovation. The shift from
the confident, technocratic innovation system of the 1950s
and 1960s to the current possibilities and ambivalences of
the knowledge-based society (20) create the conditions for
reflexive innovation systems. This is because the technolo-
gies we are developing in health—such as cloning or the
“e-patient”—as elsewhere, disrupt traditional social orders
and the terms on which people engage with and understand
the meaning of, here, their health, their body, and medicine
(23). As we grapple with the promise and disturbances of
new technologies, the more we control, as Beck (2) notes,
the “less we have control.” As a result, while knowledge
itself must be subject to increasing codification, surveil-
lance, and measurement to try to harness ambivalence, the
greater capacity for innovation and learning this allows
simply means that there is greater momentum given to the
development of new and perhaps less controllable forms of
knowledge.
HTA can also be seen to be a good example of the
way social actors in a more reflexive innovation system
develop new tools and agencies that enable reflection and
evaluation (HTA has itself a socio-technology agency, of
course). Such reflexivity has, paradoxically, been routinized
through the move toward what Lynch (15) has called a
“systemic reflexivity,” whereby in late-modern society “re-
flexive monitoring takes the predominant form of cost-benefit
and risk-benefit analysis” (p. 31). In science and technol-
ogy policy, we see this expressed through the increasing
weight given to systematic review procedures, “evidence-
based” policy and practice, and other forms of assessment.
This is clearly rooted in a conception of evidence, facts, and
judgment that is very much more in line with a Kuhnian
“normal” (13)—rather than “postnormal”—science. In ac-
knowledging, even requiring, that science is applied and
meets its users’ needs, we are led to a reconfirmation of
its most “externalist” credentials and claims. It is seen in
virtually every policy arena, but especially in health research
and development (8) expressed most clearly in evidence-
based meta-analyses and systematic reviews of medical
technology sometimes accompanied by randomized con-
trolled trials.
In addition, HTA not only seeks to take (systematic)
stock of the current situation but can also act as a prospec-
tive, future-oriented technique by mobilizing claims about
emerging technologies that recruit and secure institutional
and economic resources from public and private sectors.
HTA is in part about mapping out expectations about fu-
ture social conditions as expressed through calculation of the
cost/benefit, cost-impact, and cost-effectiveness of an emerg-
ing technology. Of course, such expectations only make sense
where they are attentive to wider socio-economic changes,
such as the demographic impact of an ageing population.
Moreover, as one moves from one country to another, the
organizational, institutional, and cultural relationships that
characterize the reflexive innovation system change. Cru-
cially, this means that no technology has the same (techno-
cratically determined) path to follow but varies according to
the national socio-technical configuration in which it is mobi-
lized and evaluated (5). This can be very worrying for some
driven by—as I noted earlier—the logic of standardization
and harmonization: witness current attempts to develop in-
formation technology protocols (based on “component based
software architecture”) that are intended to iron out contin-
gency and national variation.
HTA COUNTRY STUDIES
The four studies published in this special issue are interest-
ing in that, taken together, they mark a move toward much
greater reflexivity in the theory and practice of HTA itself.
Some themes—such as the acknowledgment of the implicit
value assumptions in the determination of the contribution
a new technology makes—are apparent in all of the studies.
However, there is still an unevenly developed discourse about
the HTA process that reflects differences, I would suggest,
in national intellectual and policy cultures within which the
HTA perspective has emerged.
There are several key themes that are raised by all the
authors that are especially amenable to sociological com-
ment, or as Bauman (18) would say, “decoding.” These can
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be summarized as debates about four core issues that are
inherently “social”:
Socio-Political Process of HTA Priority
Setting and the Assumptions
on Which It Is Based
All the studies point to the way in which HTA priority setting
is a highly politicized process, involving multiple constituen-
cies of interest with distinct social priorities, reflecting dif-
ferent social interests and needs. Orvain et al. provide a very
detailed matrix that identifies the range of HTA providers
and consumers from the pharmaceutical industry, through
various Ministries, insurance agencies, health professionals,
and medical unions. Each seeks different HTA advice relating
to drug evaluation, clinical practice guidelines, assessment of
medical devices, and so on.
Yet at the same time, HTA priority setting is not driven
simply by the discrete economic and political interests of
its customers. As Carlsson observes, HTA agencies must in
practice, simply to do their job—choose a technology for
evaluation. The choice of technology to evaluate must in some
way reflect agreed health priorities: “choosing which topics
to assess is important but very difficult,” involving a complex
and lengthy process through which possible assessments are
piloted to determine whether they will be able to meet the
demands of the review process itself.
As Stevens and Milne observe, topics tend to be restricted
to technical innovation rather than the wider context of use in
service delivery and public health. Moreover, they note that
organizational, ethical, and legal considerations are typically
ignored, at least in the UK setting. And it is clear that they
are well aware of the uneven political influence that different
groups have on the priority setting process, especially their
contrast between the pharmaceutical industry and the NHS.
Symbolic, Rhetorical Role of HTA Allied to
Other Roles It Plays in the Policy Arena
Orvain et al. offer an interesting question about HTA: “is it an
element of scientific debate, a means of changing practices, a
decision aid in the public health arena, or even a step toward
exerting market control”?
It is, presumably, all of these as different priority buttons
are pushed, but more generally, and as far as Berg et al. are
concerned, HTA plays a “symbolic function” that emphasizes
the “importance of cost-awareness” more than being a tool
that has a “direct, explicit function in policy decision mak-
ing.” Indeed, it seems that, in The Netherlands at least, HTA
often performs a legitimating function that “underwrites the
position [that stakeholders] had beforehand.”
It is not evident that such a strategy will provide the
basis for managing the ambivalences that seep into deci-
sion making and disturb existing stakeholder interests. Cost-
effectiveness can, of course, always be defined in such a way
that certain criteria or parameters take precedence over others
and that thereby some stakeholders’ positions are privileged
over others. Presumably, we need to see that the symbolic
role of raising the need for cost-awareness among resource-
hungry groups does not translate into an inequitable distribu-
tion of scarce health “goods” among all stakeholders.
Tension Between the Formal,
Decontextualized, Criteria of
Evidence-Based HTA and the “Real,”
Contingent, World of Technology
Evaluation
This theme points to the social dimensions that shape the
actual determination and deployment of technology assess-
ment among its diverse end-users. It can also be expressed
as a tension between the abstract, cosmopolitan level on the
one hand, and the concrete, local level on the other, as well
as the multiplicity of social groups who shape the evaluation
process. Berg et al. stress this as one of the most important
arguments in their study, declaring that a rationalist approach
to HTA “will always remain an illusion.”
This argument also, in turn, reveals the unstable identity
and multidimensional status of the particular technologies
being evaluated. Indeed, they are not singular objects that all
stakeholders regard in the same way, as having a stable iden-
tity and purpose; rather, they are multiply defined innovations.
As Orvain et al. observe:
“. . . it is clear that viewing any object (e.g., a medical device) from
more than one angle (confrontation of expert opinions) often best
reveals the multidimensional structure of the object.”
Even if we agree with Carlsson that the very nature
of technology today creates new problems—suggesting that
there is an intrinsically problematic character to contempo-
rary innovative health technologies—we can still say that the
meaning of this character can be “multidimensional” with
regard to the “affordances” a technology has for its different
users. The notion of “affordances” can be usefully deployed
here to suggest that all technologies have different meanings
and utility values according to the ways in which they are
harnessed.
Thus, as Orvain et al. observe, “heads of medical de-
partments will want the benefits of a new technique to be
recognized, whereas administrative staff will seek advice on
a new investment at hospital or institutional level.” The sort of
decision making that may accompany this—a decentralized
process—is regarded, at least in Sweden, as problematic: as
Carlsson says, “[D]ecentralization of decision making in the
Swedish system. . . . makes it difficult to control the introduc-
tion of new technology as every county council is free to take
any decision irrespective of costs or exclusiveness.”
Is this a weakness? No, because this emphasizes the need
for socially robust science, as Nowotny et al. (17) argues—a
position that Berg et al. would share. For them, localization
is key. But what it does reveal is the translation process at
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work in ensuring assessments make sense at the local level.
As Carlsson says, “the results are not always clear from a
policy perspective . . . results . . . need to be transferred into
guidelines before they can be implemented in health care
practice.” “Transfer” means translation here. He goes on to
say that “maybe it is impossible to communicate with . . .
politicians, administrators, clinicians, nurses with one prod-
uct. Therefore, the product must become much more adapted
to the target group.” Here again, we are reminded of Orvain
et al.’s “multidimensional structure of the object.” Stevens
and Milne usefully suggests that, in the United Kingdom, na-
tional decisions made by NICE “ought to be consistent with
the informal or formal rules used elsewhere in the system.”
Given the argument here about the need to adapt, however,
“consistency” need not mean uniformity at the point of ap-
plication.
Gap Between Agreed HTA Guidelines and
How Decisions Relating to the Acquisition
of New Technologies Are Taken
Networks come in here: a key objective is to enroll—
to ensure “strong collaboration” between different social
agencies/customers engaging with HTA. Berg et al. stress
the social network among the key actors—which in The
Netherlands is expressed as a system of “interdependencies”
between government, providers, insurers, and patient groups.
Carlsson also notes that it is difficult to give a “compre-
hensive answer” to the actual use of HTA studies by policy
makers.
Can these gaps (also noted by Stevens and Milne) be
resolved through improving the methodology or process
of HTA? There are various perspectives on this: Orvain
et al.’s rationalist model—a very French tradition perhaps—
advocates giving health professionals tools to evaluate quality
such that they will become more accepting of HTA itself,
presumably by means of a process of professional transfer-
ence. Expertise and consensus go hand in hand . . . but how
many hands are there? And how does this position tie-in with
the translation process acknowledged earlier? Berg et al., on
the other hand, want to see formalized HTA drawing on—
rather than distancing itself from—“the experience, imagina-
tion and intuition” of those engaged in the delivery of health
care.
This problem of how to manage the “gap” between
national HTA and local practice is echoed at an international
level: that is, national cultural variation in HTA produces
some different types of gap reflecting broad differences in
political cultures. At the same time, wider social conditions—
such as an ageing population—mean that the value of new
technologies (already sensitive to demographic factors) can
only be effectively understood if we develop more sensitive
measures of a nonhomogenous variety: the ageing population
will in fact be quite heterogeneous in its health demands and
needs.
CONCLUSIONS
The four studies raise several themes that relate directly to
the question of social coordination of HTA. First, they report
different degrees of centralization in decision making, the net-
works and agencies that are involved in this, and how closely
they are integrated in the process of HTA and priority setting,
with the United Kingdom being highly centrist, the Dutch
corporatist, the French system comprising a set of discrete
agencies, and the Swedish system being highly decentral-
ized with considerable autonomy for county and municipal
councils. From a sociological perspective, we need to un-
derstand how these varying institutional configurations are
more, or less, likely to facilitate the mobilization and diffusion
of HTA guidelines. As Berg et al. observe, the Dutch system
in practice is made up of a series of mutual interdependencies
“between government, the private (not-for-profit) service
organizations and insurers and independent profession-
als.” They complain, however, that formal HTA-informed
guidance appears not only to ignore the opportunities these
dependencies offer, but actively to displace them in favor of
“explicit knowledge laid down in rules, procedures, protocols
and manuals.”
Second, the studies refer with differing degrees of
emphasis to the way in which HTA is only “part of the
picture”—Orvain et al. note that “HTA cannot be dissociated
from the settings in which the technology is or will be used.”
Stevens and Milne argue similarly, while Berg et al. note that
guidelines are evidence-based and do not indicate whether
intervention is appropriate according to some wider values.
Carlsson argues that, in addition, the sort of “picture” that
HTA actors produce might be coloured to reflect particular
interests: as he observes “we cannot expect that the scientific
literature or the producers of pharmaceuticals and other
biomedical technologies will provide decision makers with
all [the] unbiased information they need.”
Third, the studies suggest the need for early engagement
with new technologies so as to track potential opportuni-
ties, costs, and risks posed by them. How “early” an “early
warning system” can operate depends of course on what one
is trying to monitor, what techniques are available, and who
is deemed worthy of participation. There are many different
models for this from the more technocratic to the highly inclu-
sionary Constructive Technology Assessment found (outside
of HTA) particularly in The Netherlands and Denmark.
Drawing on research undertaken in the sociology of
science and technology, there are some closing remarks that
can be made that raise issues that those working in HTA
should be considering:
First, are new health technologies significantly different
from the past, especially in their tendency toward greater tech-
nical interdependency: can HTA address, in other words, the
interlinkage of new technologies more systematically rather
than focus on discrete new developments? Developments
across the health-care system relating to “infomedicine” (9)
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and biomedicine might call for more complex forms of
assessment than those currently used (24).
Second, when HTA is undertaken, what are the “success”
criteria being used: are they identical/universal across fields?
This is an issue relating to the validation of the instruments
and criteria found in HTA. HTA is a technology itself that
needs assessment. Do more complex interventions need new
methodologies that are more cognizant of context of use?
For example, Heaton (11) has examined the domestication
(in the home) of life-sustaining technologies that were orig-
inally developed for use in a hospital setting. The meaning,
combination, use, and effectiveness and efficacy of the
home-based devices and systems (such as assisted ventila-
tion and intravenous feeding) is quite different in this setting,
where complex care regimens have to be managed in the home
by their families in conjunction with statutory and voluntary
services.
Finally, at a regulatory and institutional level, how is it
possible to mobilize assessment across different political and
clinical networks that have differing priorities? This is true
in any priority-setting domain, as is evident, for example,
in recent work on the diffusion of Foresight (22). Carlsson
comments that considerable resources have had to be put
into the dissemination process in Sweden, indicating that
“the evidence-base” does not “speak for itself”, but needs
a persuasive advocate. Berg et al. point out that HTA has had
less impact in The Netherlands with regard to government
using it to make “tough policy decisions.” At the same time,
they note that, because HTA only produces “guidelines” even
with strong steering from government, enforcement would
be equally problematic. The medical profession often wel-
comes this inasmuch as it reinforces medical discretion, yet
at the same time, as Berg et al. note, this not only places the
burden of decision making on the physician, it also reduces
the transparency and accountability of such decisions.
One response to this is for HTA to become more open
to alternative sources of information and “expertise,” to de-
monopolize (12) its position in advice giving. Rather than
seeing this as a recipe for a weakening of the science base we
can argue that where evidence survives such an interrogation
it is more socially robust. As de Jong argues: “Institutional
structures where information provision for policy making
has been demonopolised put scientific concepts to tougher
tests than structures where one dominant view or perspec-
tive is embraced by only a few influential actors” (p. 198).
Indeed, such de-monopolization is happening anyway, not
least because of the massive growth of information sourcing
by means of the Internet (6); this creates a different form
of lay-driven HTA that conventional HTA should address.
This suggests the need for new types of methodologies for
assessment that incorporate these perspectives (and not just
those relating to expert clinicians). Models for this exist with
regard to research and assessment being not merely funded
by, but actually undertaken among patient and lay groups—
what Callon (7) calls “research in the wild.” The four studies
do appear to endorse this view in their concluding remarks,
best captured by Carlsson’s comment relating to the growth of
“patient and public involvement in decision making.” While
the cynic in the United Kingdom might regard NICE’s recent
establishing of a “Citizens Council” as something through
which it can legitimate its more contentious decisions, it
might actually create greater involvement by the lay public
in decision making.
This embedding of HTA practice in wider society should
actually strengthen not only policy making but the science
and methodology of assessment itself, because the greater
the number of hoops HTA has to jump through, the more
reliable and socially resilient its knowledge claims will be-
come. This is, we might say, to survive a social rather than
simply methodological falsificationism. The gaps in HTA
noted above, are not filled through more and more evidence-
based technical expertise, but by acknowledging that they can
only be bridged through embracing the logic of a reflexive
innovation system.
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